首页> 外文期刊>Biotechnology and Bioengineering >The dynamics of the CHO host cell protein profile during clarification and protein A capture in a platform antibody purification process
【24h】

The dynamics of the CHO host cell protein profile during clarification and protein A capture in a platform antibody purification process

机译:在平台抗体纯化过程中,在澄清和蛋白A捕获过程中,CHO宿主细胞蛋白谱的动态变化

获取原文
获取原文并翻译 | 示例
           

摘要

Recombinant protein products such as monoclonal antibodies (mAbs) for use in the clinic must be clear of host cell impurities such as host cell protein (HCP), DNA/RNA, and high molecular weight immunogenic aggregates. Despite the need to remove and monitor HCPs, the nature, and fate of these during downstream processing (DSP) remains poorly characterized. We have applied a proteomic approach to investigate the dynamics and fate of HCPs in the supernatant of a mAb producing cell line during early DSP including centrifugation, depth filtration, and protein A capture chromatography. The primary clarification technique selected was shown to influence the HCP profile that entered subsequent downstream steps. MabSelect protein A chromatography removed the majority of contaminating proteins, however using 2D-PAGE we could visualize not only the antibody species in the eluate (heavy and light chain) but also contaminant HCPs. These data showed that the choice of secondary clarification impacts upon the HCP profile post-protein A chromatography as differences arose in both the presence and abundance of specific HCPs when depth filters were compared. A number of intracellularly located HCPs were identified in protein A elution fractions from a Null cell line culture supernatant including the chaperone Bip/GRP78, heat shock proteins, and the enzyme enolase. We demonstrate that the selection of early DSP steps influences the resulting HCP profile and that 2D-PAGE can be used for monitoring and identification of HCPs post-protein A chromatography. This approach could be used to screen cell lines or hosts to select those with reduced HCP profiles, or to identify HCPs that are problematic and difficult to remove so that cell-engineering approaches can be applied to reduced, or eliminate, such HCPs.
机译:用于临床的重组蛋白产品(例如单克隆抗体(mAb))必须不含宿主细胞杂质,例如宿主细胞蛋白(HCP),DNA / RNA和高分子量免疫原性聚集体。尽管需要删除和监视HCP,但在下游处理(DSP)期间它们的性质和结局仍然很差。我们已应用蛋白质组学方法研究了早期DSP(包括离心,深度过滤和A蛋白捕获色谱)中产生mAb的细胞系上清液中HCP的动力学和命运。已显示所选的主要澄清技术会影响进入后续下游步骤的HCP曲线。 MabSelect蛋白A色谱除去了大部分污染蛋白,但是使用2D-PAGE,我们不仅可以观察洗脱液中的抗体种类(重链和轻链),还可以观察到污染的HCP。这些数据表明,进行二级澄清的选择会影响蛋白A色谱后的HCP谱图,因为当比较深度滤池时,特定HCP的存在和丰度都会产生差异。在Null细胞系培养上清液的蛋白A洗脱级分中鉴定出许多位于细胞内的HCP,包括伴侣Bip / GRP78,热休克蛋白和酶烯醇化酶。我们证明早期DSP步骤的选择会影响所得的HCP谱,并且2D-PAGE可用于监测和鉴定蛋白A色谱后的HCP。该方法可用于筛选细胞系或宿主,以选择HCP谱降低的细胞,或鉴定有问题且难以去除的HCP,从而可将细胞工程方法应用于减少或消除此类HCP。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号